Literature DB >> 20889565

Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas.

Nicola Amodio1, Marianna Scrima, Lucia Palaia, Ali Naeem Salman, Alfina Quintiero, Renato Franco, Gerardo Botti, Pino Pirozzi, Gaetano Rocco, Nicla De Rosa, Giuseppe Viglietto.   

Abstract

Loss of the PTEN tumor suppressor gene occurs frequently in non-small-cell lung carcinoma (NSCLC), although neither genetic alterations nor epigenetic silencing are significant predictors of PTEN protein levels. Since recent reports implicated neural precursor cell expressed, developmentally down-regulated 4-1 (NEDD4-1) as the E3 ubiquitin ligase that regulates PTEN stability, we investigated the role of NEDD4-1 in the regulation of PTEN expression in cases of NSCLC. Our findings indicate that NEDD4-1 plays a critical role in the development of NSCLC and provides novel insight on the mechanisms that contribute to inactivate PTEN in lung cancer. Immunohistochemical analysis on tissue microarrays containing 103 NSCLC resections revealed NEDD4-1 overexpression in 80% of tumors, which correlated with the loss of PTEN protein (n=98; P<0.001). Accordingly, adoptive NEDD4-1 expression in NSCLC cells decreased PTEN protein stability, whereas knock-down of NEDD4-1 expression decreased PTEN ubiquitylation and increased PTEN protein levels. In 25% of cases, NEDD4-1 overexpression was due to gene amplification at 15q21. In addition, manipulation of NEDD4-1 expression in different lung cell systems demonstrated that suppression of NEDD4-1 expression significantly reduced proliferation of NSCLC cells in vitro and tumor growth in vivo, whereas NEDD4-1 overexpression facilitated anchorage-dependent and independent growth in vitro of nontransformed lung epithelial cells that lack pRB and TP53 (BEAS-2B). NEDD4-1 overexpression also augmented the tumorigenicity of lung cancer cells that have an intact PTEN gene (NCI-H460 cells).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889565      PMCID: PMC2966817          DOI: 10.2353/ajpath.2010.091075

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

2.  NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.

Authors:  Xinjiang Wang; Lloyd C Trotman; Theresa Koppie; Andrea Alimonti; Zhenbang Chen; Zhonghua Gao; Junru Wang; Hediye Erdjument-Bromage; Paul Tempst; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Xuejun Jiang
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

3.  PIK3CA mutation status in Japanese lung cancer patients.

Authors:  Osamu Kawano; Hidefumi Sasaki; Katsuhiko Endo; Eriko Suzuki; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2006-08-22       Impact factor: 5.705

4.  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

Authors:  Hideki Endoh; Yasushi Yatabe; Takayuki Kosaka; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

Review 5.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.

Authors:  Megan Cully; Han You; Arnold J Levine; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

6.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

7.  The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization.

Authors:  Fatemeh Fouladkou; Tamara Landry; Hiroshi Kawabe; Antje Neeb; Chen Lu; Nils Brose; Vuk Stambolic; Daniela Rotin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

8.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Authors:  Lao H Saal; Sofia K Gruvberger-Saal; Camilla Persson; Kristina Lövgren; Mervi Jumppanen; Johan Staaf; Göran Jönsson; Maira M Pires; Matthew Maurer; Karolina Holm; Susan Koujak; Shivakumar Subramaniyam; Johan Vallon-Christersson; Håkan Olsson; Tao Su; Lorenzo Memeo; Thomas Ludwig; Stephen P Ethier; Morten Krogh; Matthias Szabolcs; Vundavalli V V S Murty; Jorma Isola; Hanina Hibshoosh; Ramon Parsons; Ake Borg
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

9.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.

Authors:  Donatella Malanga; Marianna Scrima; Carmela De Marco; Fernanda Fabiani; Nicla De Rosa; Silvia De Gisi; Natalia Malara; Rocco Savino; Gaetano Rocco; Gennaro Chiappetta; Renato Franco; Virginia Tirino; Giuseppe Pirozzi; Giuseppe Viglietto
Journal:  Cell Cycle       Date:  2007-12-26       Impact factor: 4.534

10.  PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.

Authors:  W T Lim; W H Zhang; C R Miller; J W Watters; F Gao; A Viswanathan; R Govindan; H L McLeod
Journal:  Oncol Rep       Date:  2007-04       Impact factor: 3.906

View more
  60 in total

1.  Research Resource: A Dual Proteomic Approach Identifies Regulated Islet Proteins During β-Cell Mass Expansion In Vivo.

Authors:  Signe Horn; Jeannette S Kirkegaard; Soraya Hoelper; Philip A Seymour; Claude Rescan; Jens H Nielsen; Ole D Madsen; Jan N Jensen; Marcus Krüger; Mads Grønborg; Jonas Ahnfelt-Rønne
Journal:  Mol Endocrinol       Date:  2015-12-09

2.  Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.

Authors:  Giulia Marvaso; Agnese Barone; Nicola Amodio; Lavinia Raimondi; Valter Agosti; Emanuela Altomare; Valerio Scotti; Angela Lombardi; Roberto Bianco; Cataldo Bianco; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

3.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal:  Cell Cycle       Date:  2017-04-05       Impact factor: 4.534

4.  Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.

Authors:  C Xu; C D Fan; X Wang
Journal:  Oncogene       Date:  2014-01-13       Impact factor: 9.867

5.  Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6.

Authors:  Ming Sun; Jinyang Cai; Richard A Anderson; Yue Sun
Journal:  J Biol Chem       Date:  2016-08-24       Impact factor: 5.157

6.  Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells.

Authors:  Wu Wen; Jingying Li; Longwang Wang; Yifei Xing; Xuechao Li; Hailong Ruan; Xiaoqing Xi; Jianhua Xiong; Renrui Kuang
Journal:  Cell Cycle       Date:  2017-07-26       Impact factor: 4.534

Review 7.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

8.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 9.  NEDD4: a promising target for cancer therapy.

Authors:  Xiantao Ye; Lixia Wang; Bingxue Shang; Zhiwei Wang; Wenyi Wei
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

10.  NEDD4 promotes cell growth and motility in hepatocellular carcinoma.

Authors:  Hailun Zheng; Xiquan Ke; Dapeng Li; Qiangwu Wang; Jianchao Wang; Xiaoyang Liu; Min Deng; Xiaojing Deng; Yongju Xue; Yu Zhu; Qizhi Wang
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.